Home
Product
Antibody
Biosimilar Antibodies
CLEC4C (US20150299325A1 Biosimilar) Recombinant Monoclonal Antibody

CLEC4C (US20150299325A1 Biosimilar) Recombinant Monoclonal Antibody

Code: CSB-RA855470MB1HU

Rate （N/A）
Review （0）

Size:

100ug

100ug500ug1mg5mg10mg50mg100mg200mg

US$199

Quantity:

Species Reactivity: Human

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

Q8WTT0

Alternative Names

C-type lectin domain family 4 member C；Blood dendritic cell antigen 2；BDCA-2；C-type lectin superfamily member 7；Dendritic lectin；CD antigen CD303, CLEC4C, BDCA2 CLECSF11 CLECSF7 DLEC HECL

Species Reactivity

Human

Immunogen

Recombinant Human CLEC4C protein

Conjugate

Non-conjugated

Clonality

Monoclonal

Buffer

0.01M PBS，pH7.4

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Notes

Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.

Lead Time

In stock
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Concentration

It differs from different batches. Please contact us to confirm it.

Usage

It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Datasheet & COA

Antibody FAQs

Description

This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody described in US20150299325A1, specifically targeting CLEC4C (C-type lectin domain family 4 member C), also known as BDCA-2 or CD303. CLEC4C is a type II transmembrane receptor predominantly expressed on plasmacytoid dendritic cells (pDCs), where it functions as an endocytic receptor and plays a critical role in regulating innate immune responses. Upon ligand binding, CLEC4C triggers inhibitory signaling that suppresses TLR7/9-mediated interferon-alpha production by pDCs. This regulatory mechanism is particularly relevant in autoimmune diseases such as systemic lupus erythematosus and psoriasis, where aberrant pDC activation contributes to pathogenesis, as well as in cancer immunology where pDCs influence tumor microenvironments.

The reference antibody serves as a valuable research tool for investigating pDC biology, immune regulation, and CLEC4C-mediated signaling pathways. This biosimilar antibody enables researchers to explore the therapeutic potential of targeting CLEC4C in autoimmune disorders and to study pDC function in various disease contexts including viral infections and malignancies.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

Lectin-type cell surface receptor which may play a role in antigen capturing by dendritic cells. Specifically recognizes non-sialylated galactose-terminated biantennary glycans containing the trisaccharide epitope Gal(beta1-3/4)GlcNAc(beta1-2)Man. Binds to serum IgG. Efficiently targets ligand into antigen-processing and peptide-loading compartments for presentation to T-cells. May mediate potent inhibition of induction of IFN-alpha/beta expression in plasmacytoid dendritic cells. May act as a signaling receptor that activates protein-tyrosine kinases and mobilizes intracellular calcium.

Gene References into Functions

Identification of serum glycoprotein ligands for the immunomodulatory receptor blood dendritic cell antigen 2. PMID:29796630
decrease in the surface expression of CLEC4C and the endoplasmic reticulum localization of the mutant construct were observed PMID:26943047
Human BDCA2+CD123+CD56+ dendritic cells (DCs) related to blastic plasmacytoid dendritic cell neoplasm represent a unique myeloid DC subset. PMID:25779340
BDCA-2 binds selectively to glycans containing the epitope Galbeta1-3/4GlcNAcbeta1-2Man. PMID:25995448
We show the crystal structures of a carbohydrate recognition domain (CRD) of human C-type lectin receptor blood dendritic cell antigen-2 (BDCA2). PMID:24425442
Reduction in Treg numbers following Ag delivery to BDCA2 restored both CD4(+) T cell activation and Ab responses, demonstrating that Tregs were required for the observed tolerance. PMID:24829416
Data show that HCV envelope glycoprotein E2 is a novel ligand of blood dendritic cells antigen 2 (BDCA-2). PMID:23053572
Human C-type lectin domain family 4, member C (CLEC4C/BDCA-2/CD303) is a receptor for asialo-galactosyl-oligosaccharides. PMID:21880719
Accumulation of BDCA-1 and BDCA-2 around neovessels showed that mDCs and pDCs are recruited to advanced arteriosclerotic plaques. PMID:21436634
Expression of dendritic cell markers CD11c/BDCA-1 and CD123/BDCA-2 in coronary artery disease upon activation in whole blood. PMID:20888334
Indoleamine 2,3-deoxigenase positive plasmacytoid dentritic cells are the classical BDCA2 positive cells in melanoma lymph nodes PMID:19829303
Data suggest that by associating with Fc epsilon RI gamma, BDCA2 activates a novel BCR-like signaling pathway to regulate the immune functions of plasmacytoid dendritic cells. PMID:17850179
Triggering CD303 leads to tyrosine phosphorylation of Syk, Slp65, PLCgamma2 and cytoskeletal proteins. CD303 signaling is linked with internalization by clathrin-mediated endocytosis. PMID:18022864
results suggest that downregulation of BDCA2 expression on plasmacytoid dendritic cells (pDCs) may reflect the activation of pDCs accumulated in systemic lupus erythematosus patients & may be one marker for indication of disease activity of SLE patients PMID:18684674
Engagement of BDCA-2 blocks TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. PMID:19577819

Hide All

Subcellular Location

Cell membrane; Single-pass type II membrane protein.

Tissue Specificity

Expressed in plasmacytoid dendritic cells (PDCs). Constitutively expressed in immature monocyte-derived dendritic cells (iMDDC) and is significantly down-regulated upon maturation with LPS but not with TNF-alpha.

Database Links

HGNC: 13258

UNIGENE: Hs.351812

KEGG: hsa:170482

STRING: 9606.ENSP00000353500

OMIM: 606677

Promotions